Skip to main content
. 2022 Nov 11;13:6828. doi: 10.1038/s41467-022-34665-z

Fig. 6. Increasing Foxf2 sensitizes RM-1 to immune checkpoint inhibitors.

Fig. 6

a Schematic illustration of experimental design. Images of RM-1 tumors grown subcutaneously with control and Foxf2-expressing mouse prostate stromal cells with and without treatment of anti-CTLA4 (b) (N = 10) or anti-PD1 (c) (N = 9), Bar = 1 cm. Line charts show means ± s.d. of tumor volumes. Two-way ANOVA with Tukey’s multiple comparison test. FACS analysis of T cells (d) and T cells expressing Ifnγ or Gzmb (e) in RM-1 tumors grown with control and Foxf2-expressing stromal cells with and without treatment by anti-CTLA4 or anti-PD1. Data represent means ± s.d. from 6 independent tumors, except that N = 5 for analysis of Tnfα in anti-PD1 group in Fig. 6e. Two-way ANOVA with Tukey’s multiple comparison test. f qRT-PCR of gene expression in FACS-isolated CD3+ T cells from RM-1 tumors in b and c. Data represent means ± s.d. from 3 specimens. Two-way ANOVA with Tukey’s multiple comparison test. g FACS analysis of monocytic (M-) and polymorphonuclear (PMN-) myeloid derived suppressor cells (MDSC) and MHCII+CD206- M1 and CD206+ M2 macrophage in RM-1 tumors grown with control and Foxf2-expressing stromal cells with and without treatment by anti-CTLA4 or anti-PD1. Data represent means ± s.d. from 6 independent tumors. Two-way ANOVA with Tukey’s multiple comparison test. Source data are provided as a Source Data file.